The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Apellis Pharmaceuticals Inc shares valued at $280,300 were sold by Sullivan Timothy Eugene on Oct 21 ’25. At $28.03 per share, Sullivan Timothy Eugene sold 10,000 shares. The insider’s holdings dropped to 110,936 shares worth approximately $2.22 million following the completion of this transaction.
Also, Sullivan Timothy Eugene purchased 10,000 shares, netting a total of over 280,300 in proceeds.
Before that, Watson David O. had sold 5,000 shares from its account. In a trade valued at $126,100, the General Counsel traded Apellis Pharmaceuticals Inc shares for $25.22 each. Upon closing the transaction, the insider’s holdings decreased to 5,000 shares, worth approximately $2.28 million.
As published in their initiating research note from Wolfe Research on November 06, 2025, Apellis Pharmaceuticals Inc [APLS] has been a Peer perform. Analysts at Wells Fargo started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid October. As of September 26, 2025, Goldman has decreased its “Neutral” rating to a “Sell” for APLS. Earlier on May 09, 2025, Raymond James downgraded its rating. Their new recommendation was “an Outperform” for APLS stock which previously was a “a Strong buy”.
Analyzing APLS Stock Performance
On last trading session, Apellis Pharmaceuticals Inc [NASDAQ: APLS] rose 2.61% to $20.02. The stock’s lowest price that day was $19.42, but it reached a high of $20.16 in the same session. During the last five days, there has been a surge of approximately 0.35%. Over the course of the year, Apellis Pharmaceuticals Inc shares have dropped approximately -33.22%. Shares of the company reached a 52-week high of $35.57 on 01/07/25 and a 52-week low of $16.10 on 05/15/25.
Support And Resistance Levels for Apellis Pharmaceuticals Inc (APLS)
According to the 24-hour chart, there is a support level at 19.57, which, if violated, would cause prices to drop to 19.13. In the upper region, resistance lies at 20.31. The next price resistance is at 20.61. RSI (Relative Strength Index) is 37.21 on the 14-day chart, showing neutral technical sentiment.
Is Apellis Pharmaceuticals Inc subject to short interest?
Stocks of Apellis Pharmaceuticals Inc saw a sharp steep in short interest on 2025-10-31 dropping by -5.83 million shares to 15.21 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 21.05 million shares. A decline of -38.35% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.24 of the overall float, the days-to-cover ratio (short ratio) decline to 5.24.
Which companies own the most shares of Apellis Pharmaceuticals Inc (APLS)?
In terms of Apellis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 27 in the next 12 months, up nearly 38.39% from the previous closing price of $19.51. Analysts anticipate Apellis Pharmaceuticals Inc stock to reach 52 by 2025, with the lowest price target being 18. In spite of this, 14 analysts ranked Apellis Pharmaceuticals Inc stock as Buy at the end of 2025. On May 09, 2025, BofA Securities assigned a price target of “a Neutral” to the stock and downgraded coverage with a $23.
